Welcome to the international HTA database

Showing [23369 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2016	National Institute for Health and Care Excellence (NICE)	Elbasvirgrazoprevir for treating chronic hepatitis C. NICE technology appraisal guidance 413
2016	NIHR Health Technology Assessment programme	Antidepressant Controlled Trial For Negative Symptoms In Schizophrenia (ACTIONS): a double-blind, placebo-controlled, randomised clinical trial
2016	Agency for Healthcare Research and Quality (AHRQ)	Nonpharmacologic interventions for agitation and aggression in dementia
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Nivolumab in advanced melanoma treament
2016	National Institute for Health and Care Excellence (NICE)	Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma. NICE technology appraisal guidance 414
2016	Agency for Healthcare Research and Quality (AHRQ)	Treatments for fecal incontinence
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Glifing method to treat dyslexia
2016	Basque Office for Health Technology Assessment (OSTEBA)	[Design and validation of a screening tool for evaluating the health impact of regional policies]
2016	National Institute for Health and Care Excellence (NICE)	Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor. NICE technology appraisal guidance 415
2016	Agency for Healthcare Research and Quality (AHRQ)	Treatment strategies for patients with lower extremity chronic venous disease (LECVD)
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Magnetic resonance imaging with tractography for brain white matter diseases
2016	Basque Office for Health Technology Assessment (OSTEBA)	[Evaluation of care times for the main cancer sites: colon/rectum, lung, breast and prostate]
2016	National Institute for Health and Care Excellence (NICE)	Nivolumab for previously treated advanced renal cell carcinoma. NICE technology appraisal guidance 417
2016	NIHR Health Technology Assessment programme	The HubBLe Trial: haemorrhoidal artery ligation (HAL) versus rubber band ligation (RBL) for symptomatic second- and third-degree haemorrhoids: a multicentre randomised controlled trial and health-economic evaluation
2016	Agency for Healthcare Research and Quality (AHRQ)	Retinal prostheses in the Medicare population
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Percutaneous epidural neurolysis and endoscopic neurolysis for the treatment of chronic low back pain
2016	Basque Office for Health Technology Assessment (OSTEBA)	[Impact of the implementation of EFQM in Osakidetza]
2016	National Institute for Health and Care Excellence (NICE)	Dapagliflozin in triple therapy for treating type 2 diabetes. NICE technology appraisal guidance 418
2016	Agency for Healthcare Research and Quality (AHRQ)	Renal denervation in the Medicare Population
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Trigeminal nerve stimulation to treat neuralgia
2016	Basque Office for Health Technology Assessment (OSTEBA)	[Prevention of Type 2 Diabetes Mellitus in Primary Health Care through healthy lifestyles: care and recommended clinical interventions]
2016	National Institute for Health and Care Excellence (NICE)	Apremilast for treating moderate to severe plaque psoriasis. NICE technology appraisal guidance 419
2016	NIHR Health Technology Assessment programme	Clinical effectiveness and cost-effectiveness of physiotherapy and occupational therapy versus no therapy in mild to moderate Parkinson s disease: a large pragmatic randomised controlled trial (PD REHAB)
2016	NIHR Health Technology Assessment programme	Tackling obesity in areas of high social deprivation: clinical effectiveness and cost-effectiveness of a task-based weight management group programme a randomised controlled trial and economic evaluation
2016	NIHR Health Technology Assessment programme	Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation
2016	NIHR Health Technology Assessment programme	Accurate diagnosis of latent tuberculosis in children, people who are immunocompromised or at risk from immunosuppression and recent arrivals from countries with a high incidence of tuberculosis: systematic review and economic evaluation
2016	Institut national d'excellence en sante et en services sociaux (INESSS)	[Levels of care: norms and quality standards]
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Pembrolizumab for the treatment of advanced melanoma
2016	Basque Office for Health Technology Assessment (OSTEBA)	[Assessment of factors related to the pharmaceutical expenditure in Primary Care, and prescription quality in chronic diseases]
2016	National Institute for Health and Care Excellence (NICE)	Ticagrelor for preventing atherothrombotic events after myocardial infarction. NICE technology appraisal guidance 420
2016	NIHR Health Technology Assessment programme	The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study
2016	Institut national d'excellence en sante et en services sociaux (INESSS)	[Localized prostate cancer: effectiveness and safety of treatment options]
2016	NIHR Health Technology Assessment programme	The identification and treatment of women with hyperglycaemia in pregnancy: an analysis of individual participant data, systematic reviews, meta-analyses and an economic evaluation
2016	Basque Office for Health Technology Assessment (OSTEBA)	[Impact of the implementation of a population-based cervical cancer screening program based on European recommendations (test/interval) with regard to the current situation]
2016	National Institute for Health and Care Excellence (NICE)	Everolimus with exemestane for treating advanced breast cancer after endocrine therapy. NICE technology appraisal guidance 421
2016	NIHR Health Technology Assessment programme	A multicentre, randomised controlled trial comparing the clinical effectiveness and cost-effectiveness of early nutritional support via the parenteral versus the enteral route in critically ill patients (CALORIES)
2016	Institut national d'excellence en sante et en services sociaux (INESSS)	[Use of the Oncotype DX® test for therapeutic decision-making in the context of treating invasive breast cancer]
2016	NIHR Health Technology Assessment programme	Placental growth factor (alone or in combination with soluble fms-like tyrosine kinase 1) as an aid to the assessment of women with suspected pre-eclampsia: systematic review and economic analysis
2016	Basque Office for Health Technology Assessment (OSTEBA)	[An image-guided system for liver surgery (CAScination)]
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Aclidinium bromide - Benefit assessment according to §35a Social Code Book V]
2016	National Institute for Health and Care Excellence (NICE)	Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 422
2016	Institut national d'excellence en sante et en services sociaux (INESSS)	[Tonsil surgery: comparison of intracapsular dissections and extracapsular dissections and dentification of children at risk for hemorrhage]
2016	NIHR Health Technology Assessment programme	Orthotic management of instability of the knee related to neuromuscular and central nervous system disorders: systematic review, qualitative study, survey and costing analysis
2016	Health Quality Ontario (HQO)	Levonorgestrel-releasing intrauterine sSystem (52 mg) for idiopathic heavy menstrual bleeding: a health technology assessment
2016	Basque Office for Health Technology Assessment (OSTEBA)	[Economic analysis of peripherally inserted central venous catheters (PICC), inserted by nursing staff, in cancer and hematological patients]
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Nivolumab - Addendum to Commission A15-32]
2016	National Institute for Health and Care Excellence (NICE)	Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens. NICE technology appraisal guidance 423
2016	NIHR Health Technology Assessment programme	The use of exploratory analyses within the National Institute for Health and Care Excellence single technology appraisal process: an evaluation and qualitative analysis
2016	NIHR Public Health Research (PHR) programme	Implications for public health research of models and theories of disability: a scoping study and evidence synthesis
2016	Health Quality Ontario (HQO)	Transcatheter aortic valve implantation for treatment of aortic valve stenosis: a health technology assessment
2016	Basque Office for Health Technology Assessment (OSTEBA)	[Interventions to improve CPAP treatment adherence in patients with obstructive sleep apnea]
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab - Addendum to Commission A15-33]
2016	National Institute for Health and Care Excellence (NICE)	Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer. NICE technology appraisal guidance 424
2016	NIHR Health Technology Assessment programme	A randomised controlled trial to measure the effects and costs of a dental caries prevention regime for young children attending primary care dental services: the Northern Ireland Caries Prevention In Practice (NIC-PIP) trial
2016	NIHR Health Technology Assessment programme	Social Stories to alleviate challenging behaviour and social difficulties exhibited by children with autism spectrum disorder in mainstream schools: design of a manualised training toolkit and feasibility study for a cluster randomised controlled trial with nested qualitative and cost-effectiveness components
2016	NIHR Health Technology Assessment programme	Bladder ultrasonography for diagnosing detrusor overactivity: test accuracy study and economic evaluation
2016	NIHR Health Services and Delivery Research programme	Do-not-attempt-cardiopulmonary-resuscitation decisions: an evidence synthesis
2016	NIHR Health Services and Delivery Research programme	The Prevalence of Visual Impairment in People with Dementia (the PrOVIDe study): a cross-sectional study of people aged 60-89 years with dementia and qualitative exploration of individual, carer and professional perspectives
2016	Health Quality Ontario (HQO)	Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women at less than high risk for breast cancer: a health technology assessment
2016	Basque Office for Health Technology Assessment (OSTEBA)	[Prenatal screening for Down syndrome through fetal DNA sequencing from maternal blood]
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Tiotropium/olodaterol - Addendum to Commission A15-31]
2016	National Institute for Health and Care Excellence (NICE)	Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia. NICE technology appraisal guidance 425
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Everolimus (Afinitor) for diffuse large B-cell lymphoma – maintenance therapy
2016	NIHR Health Services and Delivery Research programme	Determining the optimal model for role substitution in NHS dental services in the UK: a mixed-methods study
2016	Health Quality Ontario (HQO)	Magnetic resonance imaging as an adjunct to mammography for breast cancer screening in women at less than high risk for breast cancer: OHTAC recommendation
2016	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Acute neck and back pain: preventive interventions – Effects of physical training, manual treatment and cognitive behavioral interventions]
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pertuzumab - Addendum to Commission A15-34]
2016	National Institute for Health and Care Excellence (NICE)	Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia. NICE technology appraisal guidance 426
2016	NIHR Health Technology Assessment programme	Clinical effectiveness and cost-effectiveness of body psychotherapy in the treatment of negative symptoms of schizophrenia: a multicentre randomised controlled trial
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Dabrafenib (Tafinlar) and trametinib (Mekinist) combination therapy for advanced BRAF mutated non-small cell lung cancer
2016	Adelaide Health Technology Assessment (AHTA)	Microwave tissue ablation for primary and secondary liver cancer
2016	Health Quality Ontario (HQO)	Levonorgestrel-releasing intrauterine system (52 mg) for idiopathic heavy menstrual bleeding: OHTAC Recommendation
2016	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Prenatal diagnosis through Next Generation Sequencing (NGS)]
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Isavuconazole - Assessment according to §35a (para. 1., sentence 10) Social Code Book V]
2016	NIHR Horizon Scanning Centre (NIHR HSC)	ADI-PEG 20 for hepatocellular carcinoma – second line
2016	Health Quality Ontario (HQO)	Transcatheter aortic valve implantation for treatment of aortic valve stenosis: OHTAC recommendation
2016	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Prenatal diagnosis through Chromosomal Microarray Analysis (CMA)]
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Searches in trial registries for studies on newly approved drugs]
2016	NIHR Health Technology Assessment programme	An observational study of Donor Ex Vivo Lung Perfusion in UK lung transplantation: DEVELOP-UK
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Heartcel for heart failure in patients at risk of incomplete revascularisation following coronary artery bypass graft
2016	NIHR Public Health Research (PHR) programme	IMPRoving Outcomes for children exposed to domestic ViolencE (IMPROVE): an evidence synthesis
2016	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Drug treatment of children with respiratory tract infections - a scoping review]
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Alirocumab - Benefit assessment according to §35a Social Code Book V]
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Furosemide sc2Wear micro-pump patch for oedema in heart failure
2016	NIHR Health Services and Delivery Research programme	Getting the most out of knowledge and innovation transfer agents in health care: a qualitative study
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Exploratory examination of the need for revision of the DMP "coronary heart disease"]
2016	NIHR Health Technology Assessment programme	A cluster randomised trial of strategies to increase cervical screening uptake at first invitation (STRATEGIC)
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Pertuzumab (Perjeta) with chemotherapy and trastuzumab for HER2-positive early breast cancer – adjuvant therapy
2016	NIHR Health Services and Delivery Research programme	Location of care for people with serious mental illness (LOCAPE): implications for service use and costs using a mixed-methods approach
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dabrafenib/trametinib - Addendum to Commissions A15-39 and A15-40]
2016	National Evidence-based Healthcare Collaborating Agency (NECA)	[Study of horizon scanning and potential health impact assessment of emerging health technology and development of operation system of H-SIGHT]
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Remestemcel-L for graft vs host disease in paediatric patients – second line
2016	Institut national d'excellence en sante et en services sociaux (INESSS)	[Models for providing care and services to patients who have concurrent mental health and substance use disorders]
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pomalidomide - Addendum to Commission A15-42]
2015	Institute for Clinical Evaluative Sciences (ICES)	The mental health of children and youth in Ontario: a baseline scorecard
2015	Agencia de Evaluacion de Tecnologias Sanitarias (AETS)	Once more a test title
2015	National Evidence-based Healthcare Collaborating Agency (NECA)	[The status and dissemination plan of clinical practice guidelines in Korea]
2015	NIHR Horizon Scanning Centre (NIHR HSC)	Pembrolizumab (Keytruda) for PD-L1 strong-positive metastatic non-small cell lung cancer – first line
2015	Institute for Clinical Effectiveness and Health Policy (IECS)	Tobramycin inhalation powder versus Tobramycin inhalation solution for cystic fibrosis
2015	Basque Office for Health Technology Assessment (OSTEBA)	[Evaluation of the use of the new tools 2.0 and the social web in the diffusion and dissemination of the products of the agencies and units of Health Technology Assessment]